CVAMC

1 stories · following the connections

Business

Arch Biopartners Announces Issuance of U.S. Patent for Its Novel Antibacterial Drug AB569, Designed to Target Chronic Infection and Antibiotic Resistance

By Nasdaq OMXMar 27, 2018, 1:08 PM UTC